About luye pharma group - LYPHF
Luye Pharma Group Ltd. is an investment holding company, which engages in the developing, producing, marketing, and selling of pharmaceutical products. It operates through the following segments: Oncology Drugs, Cardiovascular System Drugs, Alimentary Tract and Metabolism Drugs, and Others. The company was founded on June 8, 1994 and is headquartered in Yantai, China.
LYPHF At a Glance
Luye Pharma Group Ltd.
No. 15 Chuang Ye Road
Yantai, Shandong 264003
| Phone | 86-535-671-7618 | Revenue | 867.05M | |
| Industry | Pharmaceuticals: Major | Net Income | 75.17M | |
| Sector | Health Technology | Employees | 5,270 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
LYPHF Valuation
| P/E Current | 9.226 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 23.648 |
| Price to Sales Ratio | 2.054 |
| Price to Book Ratio | 1.017 |
| Price to Cash Flow Ratio | 8.027 |
| Enterprise Value to EBITDA | 9.228 |
| Enterprise Value to Sales | 2.433 |
| Total Debt to Enterprise Value | 0.563 |
LYPHF Efficiency
| Revenue/Employee | 164,525.723 |
| Income Per Employee | 14,264.384 |
| Receivables Turnover | 2.298 |
| Total Asset Turnover | 0.245 |
LYPHF Liquidity
| Current Ratio | 1.315 |
| Quick Ratio | 1.214 |
| Cash Ratio | 0.871 |
LYPHF Profitability
| Gross Margin | 68.305 |
| Operating Margin | 14.942 |
| Pretax Margin | 11.384 |
| Net Margin | 8.67 |
| Return on Assets | 2.123 |
| Return on Equity | 4.654 |
| Return on Total Capital | 2.544 |
| Return on Invested Capital | 3.748 |
LYPHF Capital Structure
| Total Debt to Total Equity | 67.224 |
| Total Debt to Total Capital | 40.20 |
| Total Debt to Total Assets | 33.047 |
| Long-Term Debt to Equity | 25.761 |
| Long-Term Debt to Total Capital | 15.405 |